Abstract:Congress Presidents H.H. Kessler, A.C. Haushofer Scientific Committee A.C. Haushofer, H.H. Kessler, B.I. Santner, R.E. Stauber, E. Stelzl Chair of the EFLM Task Force on European Regulatory Affairs, Department of Clinical Chemistry and Laboratory Medicine, Leiden University Medical Center, Leiden, The Netherlands Within the EU, laboratory or in vitro diagnostic (IVD) tests were regulated by the 1998 Directive 98/79/EC on in vitro diagnostic medical devices (IVDD), which mainly governed pre-market production within the manufacturing sector of CE-IVD marked tests. The majority were self-declared by manufacturers, with EU-wide application, and only approximately 10% required certification by notified bodies, appointed by the national competent authorities in Member States. IVDD did not regulate use of in-house devices (IH-IVD, referred to herein as IH-IVD as this is the term used in EU legislation), which are manufactured and used within the same health institution for medical purposes, in keeping with the EU principle of subsidiarity, and consequent national regulation. With the roll out of EU Regulation 2017/746 on in vitro diagnostic medical devices (IVDR), from 26 May 2022 onwards, the EU market access of medical tests -and not the use- is governed by a vastly expanded and upgraded EU regulatory framework. Notably, in-house devices (IH-IVDs) are exempted from the IVDR, except for compliance with Annex I and Art 5. An overview of the major regulatory changes (among them risk based test classification and clinical evidence generation), the amended transition timelines, the role of notified bodies, EU reference laboratories, expert panels, and the Medical Device Coordination Group (MDCG) will be presented. Laboratory medicine plays an increasingly important part in medical decision-making at diagnosis and follow-up and evolution towards "Personalized" or "Precision" medicine in all disciplines. It is, therefore, not surprising that laboratory medicine has a long standing history of self-regulation and laboratory accreditation. Therefore, accredited labs do have a sufficient fundament for manufacture and use of safe and effective IH-IVDs, and can easily embed the IVDR-requirements into their quality management system. Anno 2024, the EU regulatory framework is still under construction and <5% of the class D tests are IVDR-compliant. While large IVD-companies can cope with the new regulation, this is far more difficult for small and medium IVD-enterprises (SMEs). Because the IVDR-compliance assessment by Notified Bodies is experienced as unpredictable, cumbersome and costly, it keeps SMEs away from sufficient return-on-investment . As a consequence, essential niche and orphan disease tests are in danger of being lost, with negative impact on patient management. On top, the diagnostic sector faces two additional key challenges: (1) the stipulation on equivalence of tests (article 5.5d), which imposes restrictions on the further manufacture and use of IH-IVDs once a commercial equivalent is available and (2) the gray area between CE-marked in vitro diagnostics (CE-IVDs), modified CE-IVDs, Research Use Only (RUO) tests, and IH-IVDs. The results of a questionnaire on current diagnostic practice conducted by European medical societies collaborating in the BioMed Alliance indicate widespread use of IH-IVDs in diagnostic laboratories across Europe and emphasize the need to preserve IH-IVDs for essential innovation and for rapid test development during pandemics. Diagnostic equivalents of the European Reference Networks (ERNs) for rare diseases could help ensure affordable and equal access to specialized diagnostics across the EU. Concerted action by clinical and laboratory disciplines, regulators, industry, and patient organizations is needed to prevent discontinuation of essential low volume tests and to support the efficient and effective implementation of the IVDR in a way that preserves innovation and safeguards the quality, safety, and accessibility of innovative diagnostics. On top, a critical appraisal of the IVDR effectiveness is becoming urgent as there is no evidence so far that this enormous investment in clerical paper work, even obliged for conventional tests that have been used for decades, will improve patient management and outcome. In an era of exploding healthcare costs, time is there for considering IVDR justification and reform. In the last decade, scientific advances have laid a solid foundation for the development of routine molecular 'liquid biopsies'. Cell-free DNA and RNA biomarkers can complement or even surrogate tissue biopsy and have been introduced in clinical laboratory practice, especially in prenatal screening and oncology. Through cell-free DNA detection by real-time PCR techniques and next generation sequencing, a simple non-invasive test becomes a liquid biopsy for 1) an -Abstract Truncated-

Finding our way in the In Vitro Diagnostic Medical Devices Regulation: a discussion paper from the European Bioanalysis Forum

ISMD2024 Thirteenth International Symposium on Molecular Diagnostics

The new IVD Regulation 2017/746: a case study at a large university hospital laboratory in Belgium demonstrates the need for clarification on the degrees of freedom laboratories have to use lab-developed tests to improve patient care

Facing the new IVD Regulation 2017/746: Contract Research Organizations (CROs), key partners of IVDs manufacturers for compliance

Evaluation of Companion Diagnostics in Scientific Advice and Drug Marketing Authorization Applications by the European Medicines Agency

The challenges for implementing Good Clinical Practices in the bioanalytical laboratory: a discussion paper from the European Bioanalysis Forum

Laboratory-Developed Tests: Design of a Regulatory Strategy in Compliance with the International State-of-the-Art and the Regulation (EU) 2017/746 (EU IVDR [In Vitro Diagnostic Medical Device Regulation])

IVDR: Analysis of the Social, Economic, and Practical Consequences of the Application of an Ordinance of the In Vitro Diagnostic Ordinance in Switzerland

Recent regulatory developments in EU Medical Device Regulation and their impact on biomaterials translation

The impact of companion diagnostic testing on medical decision making and IVD regulations

Market surveillance of in vitro diagnostics by the BfArM until end 2010: safety of IVD for therapeutic drug monitoring

Principles of ideal diagnostic regulation and the IVDR

Biomarker and Companion Diagnostics—A Review of Medicinal Products Approved by the European Medicines Agency

Re-thinking the current paradigm for clinical immunogenicity assessment: an update from the discussion in the European Bioanalysis Forum

ISO 15189 is a sufficient instrument to guarantee high-quality manufacture of laboratory developed tests for in-house-use conform requirements of the European In-Vitro-Diagnostics Regulation

Reference, calibration and referral laboratories – a look at current European provisions and beyond

IVDCheckR – simplifying documentation for laboratory developed tests according to IVDR requirements by introducing a new digital tool

Analysis of the renewed European Medical Device Regulations in the frame of the non - EU regulatory landscape during the COVID facilitated change

[Safety of in-vitro diagnostics used in transfusion medicine. Experience of the BfArM until end 2005]